AR124676A2 - Formulación farmacéutica que comprende una droga biofarmacéutica - Google Patents

Formulación farmacéutica que comprende una droga biofarmacéutica

Info

Publication number
AR124676A2
AR124676A2 ARP220100101A ARP220100101A AR124676A2 AR 124676 A2 AR124676 A2 AR 124676A2 AR P220100101 A ARP220100101 A AR P220100101A AR P220100101 A ARP220100101 A AR P220100101A AR 124676 A2 AR124676 A2 AR 124676A2
Authority
AR
Argentina
Prior art keywords
biopharmaceutical drug
pharmaceutical formulation
antibodies
antibody
formulation according
Prior art date
Application number
ARP220100101A
Other languages
English (en)
Inventor
Martina Danek-Bulius
Britta Deutel
Sabine Frtinger
Bernt Pragl
Drago Kuzman
Original Assignee
Hexal Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hexal Ag filed Critical Hexal Ag
Publication of AR124676A2 publication Critical patent/AR124676A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Una formulación farmacéutica que comprende una droga biofarmacéutica, donde dicha composición además comprende por lo menos un ácido mono- o dicarboxílico con un esqueleto principal de 2 - 6 átomos de C, o por lo menos una sal del mismo. Reivindicación 8: La formulación de acuerdo con cualquiera de las reivindicaciones mencionadas anteriormente, caracterizada porque dicha droga biofarmacéutica es una proteína. Reivindicación 10: La formulación de acuerdo con cualquiera de las reivindicaciones mencionadas anteriormente, caracterizada porque dicha proteína es por lo menos un anticuerpo, o un fragmento o un derivado del mismo, que se selecciona entre el grupo que consiste en: anticuerpos derivados de hibridoma, anticuerpos quimerizados, anticuerpos humanizados, y/o anticuerpos humanos. Reivindicación 11: La formulación de acuerdo con la reivindicación 9 ó 10, caracterizada porque dicho anticuerpo, o fragmento o derivado del mismo, es un anticuerpo anti-TNFa.
ARP220100101A 2010-12-28 2022-01-18 Formulación farmacéutica que comprende una droga biofarmacéutica AR124676A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10197122A EP2471554A1 (en) 2010-12-28 2010-12-28 Pharmaceutical formulation comprising a biopharmaceutical drug

Publications (1)

Publication Number Publication Date
AR124676A2 true AR124676A2 (es) 2023-04-26

Family

ID=43982272

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP110104977A AR084627A1 (es) 2010-12-28 2011-12-28 Formulacion farmaceutica que comprende una droga biofarmaceutica
ARP220100101A AR124676A2 (es) 2010-12-28 2022-01-18 Formulación farmacéutica que comprende una droga biofarmacéutica

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP110104977A AR084627A1 (es) 2010-12-28 2011-12-28 Formulacion farmaceutica que comprende una droga biofarmaceutica

Country Status (22)

Country Link
US (1) US9480743B2 (es)
EP (2) EP2471554A1 (es)
JP (2) JP5767340B2 (es)
KR (1) KR101808367B1 (es)
CN (1) CN103269718B (es)
AR (2) AR084627A1 (es)
AU (1) AU2011351414B2 (es)
BR (1) BR112013016770A2 (es)
CA (1) CA2822859C (es)
DK (1) DK2658575T3 (es)
ES (1) ES2659981T3 (es)
HR (1) HRP20171931T1 (es)
HU (1) HUE035707T2 (es)
MX (1) MX352245B (es)
NO (1) NO2658575T3 (es)
PL (1) PL2658575T3 (es)
PT (1) PT2658575T (es)
RU (1) RU2587056C2 (es)
SI (1) SI2658575T1 (es)
TW (1) TWI530295B (es)
WO (1) WO2012089778A1 (es)
ZA (2) ZA201304446B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2471554A1 (en) 2010-12-28 2012-07-04 Hexal AG Pharmaceutical formulation comprising a biopharmaceutical drug
JP2015509526A (ja) 2012-03-07 2015-03-30 カディラ ヘルスケア リミティド 医薬製剤
US20130236505A1 (en) 2012-03-09 2013-09-12 Basf Se Production Of Pharmaceutical Protective Coatings With Good Resistance In A Neutral Environment
WO2013186230A1 (en) * 2012-06-12 2013-12-19 Boehringer Ingelheim International Gmbh Pharmaceutical formulation for a therapeutic antibody
AU2013312300A1 (en) 2012-09-07 2015-04-16 Coherus Biosciences, Inc. Stable aqueous formulations of adalimumab
WO2014100143A2 (en) * 2012-12-20 2014-06-26 Medimmune, Llc Liquid antibody formulation with improved aggregation properties
CN103446583B (zh) * 2013-03-21 2015-11-18 百奥泰生物科技(广州)有限公司 一种治疗TNF-α相关疾病的人抗体制剂
EP3021833B2 (en) * 2013-07-19 2022-03-30 Hexal Aktiengesellschaft Methods and formulations which allow the modulation of immune responses related to the administration of a biopharmaceutical drug
ES2607489T3 (es) 2014-05-23 2017-03-31 Ares Trading S.A. Composición farmacéutica líquida
EP2946766B1 (en) 2014-05-23 2016-03-02 Ares Trading S.A. Liquid pharmaceutical composition
HUE029849T2 (en) 2014-05-23 2017-04-28 Ares Trading Sa Liquid pharmaceutical composition
HUP1400510A1 (hu) 2014-10-28 2016-05-30 Richter Gedeon Nyrt Gyógyászati TNFalfa ellenes antitest készítmény
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
SG11202108627SA (en) 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation
JP2026501288A (ja) 2022-12-21 2026-01-14 フォーマイコン アーゲー 抗ｐｄ１抗体の製剤
WO2025149960A1 (en) * 2024-01-11 2025-07-17 Lupin Limited Pharmaceutical formulation of anti-il-5 antibody

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
FI903489A0 (fi) 1988-11-11 1990-07-10 Medical Res Council Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
JP3179538B2 (ja) * 1990-12-11 2001-06-25 ノバルティス アクチエンゲゼルシャフト 安定なヒトカルシトニンの水性溶液
US20040120952A1 (en) * 2000-08-07 2004-06-24 Centocor, Inc Anti-TNF antibodies and peptides of human tumor necrosis factor
US5264142A (en) 1991-11-25 1993-11-23 Lever Brothers Company, Division Of Conopco, Inc. Stabilization of peroxygen bleach in enzyme-containing heavy duty liquids
WO1997008320A1 (en) 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Protein/(poly)peptide libraries
AU2440197A (en) * 1996-04-18 1997-11-07 Baxter International Inc. Stabilization of therapeutic hemoglobin compositions
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US7087248B2 (en) * 2000-06-30 2006-08-08 Daiichi Asubio Pharma Co., Ltd. Pharmaceutical component based on human parathyroid hormone and a pharmaceutical composition for intranasal administration comprising the component
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
IL161677A0 (en) * 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
JP2005515180A (ja) * 2001-11-13 2005-05-26 ザ プロクター アンド ギャンブル カンパニー 阻害物質で安定化させた酵素を含有する局所適用組成物
ATE306810T1 (de) 2002-03-05 2005-11-15 Artemis Pharmaceuticals Gmbh Durch inzucht erzeugte von embryonalen stammzellen abgeleitete mäuse
US20030204861A1 (en) 2002-04-30 2003-10-30 Madaiah Puttaraju Transgenic animal model for spliceosome-mediated RNA trans-splicing
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
WO2004019861A2 (en) * 2002-08-28 2004-03-11 Pharmacia Corporation Stable ph optimized formulation of a modified antibody
AU2003301761A1 (en) * 2002-10-29 2004-05-25 Medical Nutrition Usa, Inc. Method for treating wounds to promote healing
US20040101939A1 (en) * 2002-11-22 2004-05-27 Santora Ling C. Method for reducing or preventing modification of a polypeptide in solution
EP1620072B1 (en) * 2003-05-01 2008-03-26 LTT Bio-Pharma Co., Ltd. Zinc-containing sustained-release composition, its preparation, and method for producing the same
JP4762717B2 (ja) * 2003-10-09 2011-08-31 中外製薬株式会社 ＩｇＭ高濃度安定化溶液
US20070184050A1 (en) * 2003-12-25 2007-08-09 Kirin Beer Kabushiki Kaisha Stable water-based medicinal preparation containing antibody
US20080090753A1 (en) * 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
KR20070107079A (ko) * 2005-01-28 2007-11-06 와이어쓰 안정화된 액체 폴리펩타이드 제형
GB0503337D0 (en) * 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
CN101166763B (zh) 2005-04-18 2012-09-19 伊达研究和发展有限公司 稳定的抗乙肝病毒(hbv)抗体配制剂
GB0707938D0 (en) * 2007-04-25 2007-05-30 Univ Strathclyde Precipitation stabilising compositions
JP2009153392A (ja) * 2007-12-25 2009-07-16 Lion Corp 液体経口用組成物
BRPI0907186A2 (pt) * 2008-01-15 2015-07-14 Abbott Gmbh & Co Kg Composições proteicas pulverizadas e métodos para sua produção
RU2653753C1 (ru) * 2008-06-25 2018-05-14 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи СТАБИЛЬНЫЕ И РАСТВОРИМЫЕ АНТИТЕЛА, ИНГИБИРУЮЩИЕ TNFα
GB0818228D0 (en) * 2008-10-06 2008-11-12 Avecia Biolog Ltd Purification process
EP2471554A1 (en) 2010-12-28 2012-07-04 Hexal AG Pharmaceutical formulation comprising a biopharmaceutical drug

Also Published As

Publication number Publication date
ES2659981T3 (es) 2018-03-20
ZA201308841B (en) 2015-02-25
ZA201304446B (en) 2014-02-26
PT2658575T (pt) 2018-02-22
MX2013007537A (es) 2014-03-13
DK2658575T3 (en) 2018-01-22
RU2013133953A (ru) 2015-02-10
EP2471554A1 (en) 2012-07-04
JP2015131832A (ja) 2015-07-23
AU2011351414B2 (en) 2017-01-19
HRP20171931T1 (hr) 2018-02-23
MX352245B (es) 2017-10-31
CN103269718A (zh) 2013-08-28
EP2658575A1 (en) 2013-11-06
KR101808367B1 (ko) 2018-01-18
TW201302223A (zh) 2013-01-16
BR112013016770A2 (pt) 2016-10-11
WO2012089778A1 (en) 2012-07-05
CA2822859C (en) 2016-11-08
EP2658575B1 (en) 2017-11-15
TWI530295B (zh) 2016-04-21
US9480743B2 (en) 2016-11-01
SI2658575T1 (en) 2018-02-28
RU2587056C2 (ru) 2016-06-10
JP2014505682A (ja) 2014-03-06
NO2658575T3 (es) 2018-04-14
HUE035707T2 (en) 2018-05-28
US20130336968A1 (en) 2013-12-19
PL2658575T3 (pl) 2018-04-30
JP5767340B2 (ja) 2015-08-19
KR20130137653A (ko) 2013-12-17
CN103269718B (zh) 2016-02-10
AU2011351414A1 (en) 2013-07-04
CA2822859A1 (en) 2012-07-05
AR084627A1 (es) 2013-05-29

Similar Documents

Publication Publication Date Title
AR124676A2 (es) Formulación farmacéutica que comprende una droga biofarmacéutica
CY1124681T1 (el) Διειδικα αντισωματα anti-vegf/anti-ang-2 και η χρηση τους στην αγωγη οφθαλμικων αγγειακων νοσων
CY1123657T1 (el) Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1
CY1122840T1 (el) Ανθρωποποιημενα ή χιμαιρικα αντισωματα cd3
AR102698A1 (es) Anticuerpos contra cd73 y sus usos
PE20191242A1 (es) Formulaciones de anticuerpo y metodos
PE20141151A1 (es) Proteinas de union al antigeno cd27l
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
AR093803A1 (es) Composiciones y metodos de anticuerpos de marcaje de epo
PE20161032A1 (es) Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion
PE20181805A1 (es) Composiciones y anticuerpos anti-tim-3
EA201992570A1 (ru) Составы на основе человеческих антител к rankl, а также способы их применения
CR20140029A (es) Proteínas de unión a antígeno de tnf-alfa con unión a fcrn incrementada
BR112012028920A2 (pt) formulações de anticorpo de alta concentração
ES2670621T3 (es) Anticuerpos que se unen a OX40 y sus usos
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
UA118441C2 (uk) Антитіло, що розпізнає альфа-синуклеїн
EA201790342A1 (ru) Антитела к trem2 и способы их применения
UA116194C2 (uk) Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном
EA201591131A1 (ru) Днк-конструкции антитела и способ их применения
EA201300137A1 (ru) Комбинированная фармацевтическая композиция и способ лечения заболеваний или состояний, связанных с нейродегенеративными зоболеваниями
EA201991704A3 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
PE20141706A1 (es) Anticuerpos de union a trombina y usos del mismo
CL2015001849A1 (es) Anticuerpos anti-lamp1 y conjugados anticuerpos fármaco, y usos de estos
UA107836C2 (uk) Метод лікування хвороби альцгеймера

Legal Events

Date Code Title Description
FB Suspension of granting procedure